Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
LA JOLLA PHARMACEUTICAL CO (LJPC)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/06/2019 |
8-K
| Quarterly results|
Docs:
|
"La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2019 and Highlights Recent Corporate Progress SAN DIEGO, CA - May 6, 2019 - La Jolla Pharmaceutical Company , a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three months ended March 31, 2019 and highlighted recent corporate progress. For the three months ended March 31, 2019, GIAPREZA net product sales were $4.4 million, compared to $0.8 million for the same period in 2018. La Jolla launched GIAPREZA in the U.S. in March 2018. La Jolla’s net loss for the three months ended March 31, 2019 was $31.7 million, or $1.17 per s..." |
|
| 03/04/2019 |
8-K
| Quarterly results |
| 10/24/2018 |
8-K
| Quarterly results|
Docs:
|
"La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2018 SAN DIEGO, CA - October 24, 2018 - La Jolla Pharmaceutical Company , a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and nine months ended September 30, 2018. For the three months ended September 30, 2018, GIAPREZA™ net product sales were $3.5 million. This compares to $1.6 million for the three months ended June 30, 2018 and $0.8 million for the three months ended March 31, 2018. La Jolla launched GIAPREZA in the U.S. in March 2018. For the nine months ended September 30, 2018, GIAPREZA net ..." |
|
| 05/14/2018 |
8-K
| Quarterly results |
| 10/27/2017 |
8-K
| Quarterly results |
| 05/01/2017 |
8-K
| Form 8-K - Current report |
| 02/23/2017 |
8-K
| Form 8-K - Current report |
| 11/09/2016 |
8-K
| Form 8-K - Current report |
| 05/11/2016 |
8-K
| Quarterly results|
Docs:
|
"La Jolla Pharmaceutical Company Announces First Quarter 2016 Financial Results and Recent Corporate Progress SAN DIEGO, CA - May 6, 2016 - La Jolla Pharmaceutical Company , a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported first quarter 2016 financial results and highlighted recent corporate progress. Recent Corporate Progress • La Jolla’s ATHOS 3 trial continued to enroll as planned through the first quarter of 2016. The ATHOS 3 trial is La Jolla’s multicenter, randomized, double-blind, placebo-controlled, Phase 3 clinical trial of LJPC-501, the Company’s proprietary formulation of angiotensin II, in catecholamine-resistant hypotension , which was initiated in 2015. The Compan..." |
|
| 03/02/2016 |
8-K
| Quarterly results |
| 11/12/2015 |
8-K
| Quarterly results |
| 08/11/2015 |
8-K
| Quarterly results |
| 05/05/2015 |
8-K
| Quarterly results |
| 03/18/2015 |
8-K
| Quarterly results |
| 11/18/2014 |
8-K
| Quarterly results |
| 05/02/2008 |
8-K
| Form 8-K - Current report |
| 05/03/2007 |
8-K
| Form 8-K - Current report |
| 05/04/2006 |
8-K
| Form 8-K - Current report |
|
|